BACKGROUND: The aim of this study was to determine whether apparent diffusion coefficient (ADC) bi-component curve-fitting histogram analysis and volume percentage change (VPC) prior to bevacizumab treatment can stratify progression-free survival (PFS) and overall survival (OS) in patients with glioblastoma multiforme (GBM) on first recurrence. METHODS: We retrospectively evaluated 17 patients with recurrent GBM who received bevacizumab and fotemustine (n = 13) or only bevacizumab (n = 4) on first recurrence at our institution between December 2009 and July 2015. Both T2/FLAIR abnormalities and enhancing tumor on T1 images were mapped to the ADC images. ADC-L and ADC-M values were obtained trough bi-Gaussian curve fitting histogram analysis. Furthermore, the study population was dichotomized into two subgroups: patients displaying a reduction in enhancing tumor volume of either >55% or <55% between the mean value calculated at baseline and first follow-up. Subsequently, a second dichotomization was performed according to a reduction in the T2 / FLAIR volume >41% or <41% at first check after treatment. OS and PFS were assessed using volume parameters in a Cox regression model adjusted for significant clinical parameters. RESULTS: In univariate analysis, contrast-enhanced (CE)-ADC-L was significantly predictive of PFS (p = 0.01) and OS (p = 0.03). When we dichotomized our sample using the 55% cut-off for enhancing tumor volume, CE-VPC was able to predict PFS (p = 0.01) but not OS (p = 0.08). In multivariate analysis, only the CE-ADC-L was predictive of PFS (p = 0.01), albeit not predictive of OS (p = 0.14). CE-ADC-M, T2/FLAIR-ADC-L, T2/FLAIR-ADC, and T2/FLAIR VPC were not significantly predictive of PFS and OS (p > 0.05) in both univariate and multivariate analysis. CONCLUSIONS: CE-ADC and CE-VPC can stratify PFS for patients with recurrent glioblastoma prior to bevacizumab treatment.
BACKGROUND: The aim of this study was to determine whether apparent diffusion coefficient (ADC) bi-component curve-fitting histogram analysis and volume percentage change (VPC) prior to bevacizumab treatment can stratify progression-free survival (PFS) and overall survival (OS) in patients with glioblastoma multiforme (GBM) on first recurrence. METHODS: We retrospectively evaluated 17 patients with recurrent GBM who received bevacizumab and fotemustine (n = 13) or only bevacizumab (n = 4) on first recurrence at our institution between December 2009 and July 2015. Both T2/FLAIR abnormalities and enhancing tumor on T1 images were mapped to the ADC images. ADC-L and ADC-M values were obtained trough bi-Gaussian curve fitting histogram analysis. Furthermore, the study population was dichotomized into two subgroups: patients displaying a reduction in enhancing tumor volume of either >55% or <55% between the mean value calculated at baseline and first follow-up. Subsequently, a second dichotomization was performed according to a reduction in the T2 / FLAIR volume >41% or <41% at first check after treatment. OS and PFS were assessed using volume parameters in a Cox regression model adjusted for significant clinical parameters. RESULTS: In univariate analysis, contrast-enhanced (CE)-ADC-L was significantly predictive of PFS (p = 0.01) and OS (p = 0.03). When we dichotomized our sample using the 55% cut-off for enhancing tumor volume, CE-VPC was able to predict PFS (p = 0.01) but not OS (p = 0.08). In multivariate analysis, only the CE-ADC-L was predictive of PFS (p = 0.01), albeit not predictive of OS (p = 0.14). CE-ADC-M, T2/FLAIR-ADC-L, T2/FLAIR-ADC, and T2/FLAIR VPC were not significantly predictive of PFS and OS (p > 0.05) in both univariate and multivariate analysis. CONCLUSIONS: CE-ADC and CE-VPC can stratify PFS for patients with recurrent glioblastoma prior to bevacizumab treatment.
Authors: Andrew D Norden; Jan Drappatz; Alona Muzikansky; Karly David; Mary Gerard; M Brenna McNamara; Phuong Phan; Ainsley Ross; Santosh Kesari; Patrick Y Wen Journal: J Neurooncol Date: 2008-11-29 Impact factor: 4.130
Authors: E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Harriet C Thoeny; Frederik De Keyzer; Vincent Vandecaveye; Feng Chen; Xihe Sun; Hilde Bosmans; Robert Hermans; Eric K Verbeken; Chris Boesch; Guy Marchal; Willy Landuyt; Yicheng Ni Journal: Radiology Date: 2005-09-28 Impact factor: 11.105
Authors: P L Nghiemphu; W Liu; Y Lee; T Than; C Graham; A Lai; R M Green; W B Pope; L M Liau; P S Mischel; S F Nelson; R Elashoff; T F Cloughesy Journal: Neurology Date: 2009-04-07 Impact factor: 9.910
Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Forrest W Crawford; Inas S Khayal; Colleen McGue; Suja Saraswathy; Andrea Pirzkall; Soonmee Cha; Kathleen R Lamborn; Susan M Chang; Mitchel S Berger; Sarah J Nelson Journal: J Neurooncol Date: 2008-11-15 Impact factor: 4.130
Authors: Rik van den Elshout; Tom W J Scheenen; Chantal M L Driessen; Robert J Smeenk; Frederick J A Meijer; Dylan Henssen Journal: Insights Imaging Date: 2022-10-04
Authors: R Kurokawa; A Baba; M Kurokawa; A Capizzano; O Hassan; T Johnson; Y Ota; J Kim; A Hagiwara; T Moritani; A Srinivasan Journal: AJNR Am J Neuroradiol Date: 2022-01-20 Impact factor: 3.825
Authors: Giuseppe Lombardi; Alessandro Spimpolo; Sara Berti; Cristina Campi; Maria Giulia Anglani; Rossella Simeone; Laura Evangelista; Francesco Causin; Giovanni Zorzi; Giancarlo Gorgoni; Mario Caccese; Marta Padovan; Vittorina Zagonel; Diego Cecchin Journal: Br J Radiol Date: 2021-11-23 Impact factor: 3.039
Authors: Clara Le Fèvre; Roger Sun; Hélène Cebula; Alicia Thiery; Delphine Antoni; Roland Schott; François Proust; Jean-Marc Constans; Georges Noël Journal: Sci Rep Date: 2022-06-22 Impact factor: 4.996